Guardant Health, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are primarily with FY2022. The supplied filing text does not provide a clear standalone Q4 income statement.
Business context
Guardant Health develops and commercializes blood- and tissue-based precision oncology tests, cancer screening products, and data and development services. Its business includes clinical testing and work with biopharmaceutical companies. Revenue remains predominantly test-driven; precision oncology testing generated 91% of FY2023 revenue.
Financial results and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $563.9 million | $449.5 million | +25% |
| Precision oncology testing revenue | $514.2 million | $392.0 million | +31% |
| Development services and other revenue | $49.7 million | $57.5 million | -14% |
| Gross profit / gross margin | $336.9 million / 59.7% | $293.2 million / 65.2% | Margin down 5.5 percentage points |
| Operating loss | $564.7 million | $544.4 million | Loss widened 4% |
| Net loss | $479.4 million | $654.6 million | Loss narrowed |
| Net cash used in operating activities | $325.0 million | $309.5 million | Use increased |
Clinical testing revenue rose 35% to $403.9 million, primarily as clinical test volume grew to approximately 172,900 from 124,800. Biopharmaceutical testing revenue rose 17% to $110.4 million; volume increased to approximately 29,900 from 26,000. Costs of revenue grew 45%, faster than revenue, contributing to lower gross margin. Research and development, sales and marketing, and general and administrative expense declined modestly year over year; FY2023 also included $83.4 million of other operating expense.
FY2023 net loss narrowed, but this does not reflect operating improvement: FY2022 included a $99.8 million fair-value adjustment to a noncontrolling-interest liability, while FY2023 included substantial investment-related gains. FY2023 other income, net, was $53.2 million, including a $79.7 million unrealized gain on Lunit shares and $29.1 million of impairment on non-marketable investments and related assets.
At year-end, cash and cash equivalents were $1.134 billion and short-term marketable debt securities were $35.1 million. The company reported $1.140 billion of convertible notes, net, representing $1.150 billion principal of 0% notes due 2027. FY2023 financing cash flow included $493.1 million in equity-offering proceeds. Management said existing cash, cash equivalents, marketable debt securities, and anticipated operating cash flows should meet anticipated cash requirements for more than 12 months from the filing date.
Changes, outlook, risks, and unusual items
- Revenue mix: Growth came mainly from clinical and biopharmaceutical test volumes; development-services and other revenue declined.
- Margins and losses: Gross margin contracted as testing costs increased faster than revenue, and operating loss widened. The company expects further operating losses in the near term and expects continued investment in clinical studies, product development, sales, and marketing.
- Liquidity and capital: Management expects resources to cover more than 12 months, but notes it may seek additional capital. Future equity or convertible issuance could dilute shareholders; debt could restrict operations.
- Patent litigation: A November 2023 jury verdict found willful infringement of two TwinStrand/University of Washington patents and awarded $83.4 million. Guardant accrued the award, plans post-trial motions and potentially an appeal, and strongly contests the verdict. Plaintiffs indicated they would seek treble damages, interest, and a future royalty.
- Government inquiry: The company is cooperating with a U.S. Attorney’s Office False Claims Act investigation concerning billing government programs for Guardant360; the outcome is uncertain.
- Commercial and regulatory exposure: Coverage and reimbursement remain variable, with payer concentration and possible retrospective adjustments. Shield’s FDA premarket approval application was submitted in March 2023; the advisory panel intended to review it. Changes to FDA oversight of laboratory-developed tests could increase requirements and costs.
- Cybersecurity: Guardant disclosed prior email-system access by an unauthorized actor who sent phishing messages, but said it was not aware of material cybersecurity incidents or threats that had impacted the business as of the filing date.
Important facts for investors to verify
- Clinical test volume, realized reimbursement, payer mix, collections, and any subsequent revenue adjustments or payer clawbacks.
- Progress on Shield’s FDA review and reimbursement prospects, and the timing and cost of related clinical programs.
- Developments in the TwinStrand litigation, including post-trial rulings, appeal, potential damages, and any ongoing royalty exposure.
- Any material developments in the Guardant360 False Claims Act investigation.
- Cash burn, the company’s stated liquidity runway, and potential financing or dilution needs.
- Performance of the Lunit investment and non-marketable investments, which affected reported non-operating results.